E Therapix Biosciences: Small IPO With Big League Potential

These risks are standard and may or may not represent the actual position facing Therapix Bio if the company quickly proves the efficacy and performance of these drugs in the pipeline. 


The key investor takeaway is that the cannabinoid sector has been one of the hottest in the market over the last year. Several high-profile stocks have gained significant market values and are making progress towards FDA approved drugs. 

The IPO of Therapix Bio brings another stock into the sector. The stock though has a minimal valuation remaining under the radar during the IPO process. Considering the normal biotech risks, the stock makes for an interesting play in a diversified portfolio willing to accept the normal risks of a small biotech. 

1 2 3 4
View single page >> |

Disclosure: No position. 

Additional disclosure: Please ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.